CLOs on the Move

ILiAD Biotechnologies

www.iliadbio.com

 
ILiAD Biotechnologies, LLC manufactures vaccines for the prevention and treatment of disease caused by Bordetella Pertussis.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.iliadbio.com
  • 230 East 15th Street Suite 1-A
    New York, NY USA 10003
  • Phone: 954.336.0777

Executives

Name Title Contact Details

Similar Companies

Glympse Bio

Glympse Bio is developing a powerful new paradigm in diagnostics to enable noninvasive and predictive monitoring of multiple human diseases.

Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people`s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world`s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Linkage Inc

Linkage Inc is a Burlington, MA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

ViroCyt

ViroCyt is the leader in the field of rapid virus quantification. Our goal is to provide the tools that deliver meaningful improvements to mission critical processes, such as vaccine manufacturing, protein expression, antiviral development and other settings where viruses play a significant role.

Inform Genomics

Inform Genomics, Inc, is a privately held company that utilizes a proprietary technology platform to discover and develop genomic-based, precision medicine products that are designed to predict, with a high degree of accuracy, clinically important outcomes that assist physicians and their patients in making individualized medical decisions. Its lead development program is in oncology supportive care, with two major products currently in development--OnPART™ and HSCT/Mucositis™--designed not only to predict a patient's risk for developing common chemotherapy-related side effects, but also to assess a patient's willingness to tolerate those side effects. The Company's novel, IP-protected technology platform capitalizes on big data storage/memory and sophisticated cloud computing technologies. It consists of proprietary Bayesian networks and other advanced bioinformatic analytics combined with validated patient assessment tools. The Company's analytics discover interactions of genes and single nucleotide polymorphisms (SNPs) that can predict clinical outcomes. Inform Genomics' goal is to be a trusted partner to health care practitioners so that they, together with their patients, can make optimal health care choices based on an individual patient's needs and values.